Table 1 Overview of fixed-target systems reported in the literature, including details on X-ray source, analyte, protein concentration, crystal concentration, and sample consumption
From: Sample delivery methods for protein X-ray crystallography with a special focus on sample consumption
Author | Device material | X-ray source, beamline | Analyte | Protein conc. (mg/mL) | Crystal conc. (particles/mL) | Sample consumption [volume/amounta] |
|---|---|---|---|---|---|---|
Silicon-based fixed-target devices | ||||||
Zarrine-Afsar et al.88 | Si | Swiss Light Source (SLS), X10S A | Lysozyme (1), ferritin (2) | (1) 60, (2) 30 | NI | <1 µL/~(1) 0.06 mg, (2) 0.03 mg |
Mueller et al.89 | Si | SLAC, LCLS, XPP | Thaumatin (1), Proteinase K (2), sperm whale myoglobin | (1) 50, (2) 20, (3) 40–50 | NI | 0.9–10.35 µL/(1) 0.05–0.52 mg, (2) 0.02–0.21 mg, (3) ~0.04–0.5 mg |
Hunter et al.41 | Si, Si3N4 | SLAC, LCLS, CXI | Rapid encystment protein | 14.4 | 1 × 109 | ~38 µLb/0.55 mg |
Roedig et al.90 | Si | Diamond Light Source, I02 | Polyhedrin, lysozyme | NI, 50 | 1–2 × 103 | 1–3 µL/0.05–0.15 mg |
Murray et al.91 | Si, Si3N4, Kapton | Stanford Synchrotron Radiation Light Source (SSRL), BL12-2 | Lysozyme | 20 | NI | <2 µL/0.04 mg |
Oghbaey et al.79 | Si | SLAC, LCLS, XPP | Myoglobin | 50–60 | NI | 60–80 µL/3–4.8 mg |
Owen et al.92 | Si, Mylar | Diamond Light Source, I24 | Orthorhombic sperm whale myoglobin | 55–60 | NI | 60–80 µL/3.3–4.8 mg |
Lieske et al.93 | Si | SLAC, LCLS, MFX, and CXI | Proteinase K (1), Thermolysin (2) | (1) 15, (2) 20 | NI | 2–3 µL for roadrunner 1, ~100 µLb for roadrunner 2/(1) 0.05 mg, (2) 0.06 mg for roadrunner 1 and (1) 1.5 mg, (2) 2 mg for roadrunner 2 |
Tolstikova et al.94 | Si | European Synchrotron Radiation Facility (ESRF), ID09 | Lysozyme (1), Proteinase K (2) | (1) 40–60, (2) 20 | NI | ~100 µLb/(1) 4–6 mg, (2) 2 mg |
Ebrahim et al.95 | Si | Diamond Light Source, I24 | Copper nitrite reductase | 20 | NI | 100–200 µL/2–4 mg |
Single polymer-based fixed-target devices | ||||||
Ng et al.96 | COC | SSRL, BL1-5 | Bacteriorhodopsin | 50 | NI | 30 µL/1.5 mg |
Pinker et al.98 | COC | SLS, X10SA and X06DA | Lysozyme (1), thaumatin (2), insulin (3) | (1) 50, (2) 30, (3) 20 | NI | ~2 µLb/(1) 0.1 mg, (2) 0.06 mg, (3) 0.04 mg |
De Wijn et al.99 | COC | SLS, PXII, and PXIII ESRF, ID30B French Synchrotron Facility (SOLEIL), PROXIMA-2A | Protease 1 (1), CCA-adding enzyme (2), lipase (3), Hemoglobin (4) | (1) 7.4, (2) 5.5, (3) 30, (4) 20 | NI | ~2 µLb/(1) 0.02 mg, (2) 0.01 mg, (3) 0.06 mg, (4) 0.04 mg |
Karpik et al. 100 | COC | SLS, PXI X06SA SwissFEL | Lysozyme | 50 | NI | ~2 µLb/0.1 mg |
Martiel et al.101 | COC | SLS, PXI | Rhodopsin-miniGo | 25 | 3.4 × 106 | ~2 µLb/0.05 mg |
Manna et al.72 | COC | ESRF, ID29 | Lysozyme | 40 | NI | 30 µL/1.2 mg |
Emamzadah et al.105 | COP | ESRF, FIP-BM30A | Lysozyme (1), trypsin (2) | (1) 22–30, (2) 25-30 | NI | 160 µL/ (1) 3.52–4.8 mg, (2) 4–4.8 mg |
Cohen et al.106 | PC | SSRL | CpI [FeFe]-hydrogenase from Clostridium pasteurianum | 30 | NI | ~2.5 µLb/0.08 mg |
Lee et al.108 | Kapton | Pohang Accelerator Laboratory X-ray Free Electron Laser (PAL XFEL) | Glucose isomerase (1), lysozyme (2) | (1) NI, (2) 50 | 3 × 108 (1), 5 × 107 (2) | 20 µL/(1) NI, (2) 1 mg |
Lee et al.109 | Kapton | PAL XFEL, NCI | Proteinase K | 80 | 5 × 107 | 15.7 µL/1.25 mg |
Nam et al.111 | Kapton | Pohang Light Source, 11C | Lysozyme | 50 | NI | ~8 µLb/0.4 mg |
Illava et al.112 | Kapton | National Synchrotron Light Source II, XF17ID2 Cornell High Energy Synchrotron Source (CHESS), ID7B2 | fluoroacetate dehalogenase (1), lysozyme (2), human glutaminase C (3) | (1) 18, (2) 100, (3) 20 | NI | 5–10 µL/(1) 0.09–0.18 mg, (2) 0.5–1 mg, (3) 0.1–0.2 mg |
Doak et al.113 | Mylar | Spring-8 Ångstrom Compact free-electron Laser (SACLA), BL2 | Lysozyme | 32 | NI | 14 µL/0.45 mg |
Feld et al.110 | SU-8 | SLAC, LCLS | Bacteriorhodopsin | 1–3 | NI | 2 µL/0.002–0.01 mg |
Saha et al.114 | SU-8 | SSRL, BL-12-1 | Lysozyme (1), Ca2+/calmodulin-dependent protein kinase II ß hub domain (2) | (1) 120, (2) 29 | NI | 4 µL/(1) 0.48 mg, (2) 0.12 mg |
Saha et al.115 | SU-8 | SSRL, BL-12-1 | Lysozyme (1), thaumatin (2), proteinase K (3) | (1) 200, (2) 25, (3) 20 | NI | 0.5 µL/(1) 0.1 mg, (2) 0.0125 mg, (3) 0.01 mg |
Multiple polymer-based fixed-target devices | ||||||
Dhouib et al.86 | PDMS, PMMA, SU-8, COP, COC | ESRF, FIP-BM30A | Lysozyme (1), thaumatin (2) | (1) 80, (2) 34–47 | NI | 1.2 µL/ (1) 0.10 mg, (2) 0.04–0.06 mg |
Guha et al.87 | COC, PDMS | LS-CAT, Argonne National Lab | Lysozyme (1), Thaumatin (2), Ribonuclease A | (1) 100, (2) 82, (3) 229 | NI | 1.4 µL/(1) 0.14 mg, (2) 0.11 mg, (3) 0.32 mg |
Khvostichenko et al.116 | COC, PDMS | Advanced Photon Source (APS), Argonne National Lab (ANL), 21-ID-F | Rhodobacter sphaeroides | 6 | NI | ~4 µL/0.2 mg |
Lyubimov et al.117 | PDMS, PMMA | SLAC, LCLS, XPP SSRL, BL 12-2 | Lysozyme | 20 | NI | ~5 µLb/0.1 mg |
Gilbile et al.118 | COC, PMMA | SSRL, BL 12-1 | Lysozyme (1), thaumatin (2), Concanavalin-A (3), Bovine Liver Catalase (4), | (1) 30, (2) 25, (3) 70, (4) 40 | NI | 8–10 µL/(1) 0.24–0.3 mg, (2) 0.2–0.25 mg, (3) 0.56–0.7 mg, (4) 0.32–0.4 mg |
Liu et al.119 | COC, PMMA | SSRL, BL 12-1 SLAC, LCLS, MFX | Lysozyme (1), thaumatin (2), | (1) 50, (2) 25 | NI | 15 µL/ (1) 0.75 mg, (2) 0.38 mg |
Sui et al.120 | COC, PMMA, Graphene | APS, ANL, 14-ID-B | Lysozyme | 80 | NI | 16 µL/1.28 mg |
Sui et al.121 | COC, PMMA, Graphene | University of Massachusetts Amherst Institute for Applied Life Sciences Biophysical Characterization Facility | Lysozyme | 80 | NI | 3.2 µL/ 0.26 mg |
Shelby et al.122 | PMMA, Graphene | SLAC, LCLS, MFX, CXI | Rapid encystment protein | 14.4 | 2.2 × 106 | ~20 µLb/0.29 mg |
Zhao et al.123 | PMMA, Mylar | Shanghai Synchrotron Radiation Facility (SSRF), BL 18U1 | Lysozyme (1), proteinase K (2) | (1) 40, (2) 25 | NI | ~6 µLb/ (1) 0.24 mg, (2) 0.15 mg |
Zhao et al.124 | PMMA, Mylar | SSRF, BL 18U1 | Lysozyme | 40 | NI | 5 µL/0.2 mg |
Carrillo et al.125 | COC, COP | SwissFEL, SwissMX | Lysozyme | 25 | 3.2 × 108 | ~1–10 µLb/0.03–0.3 mg |
